GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Debt-to-EBITDA
中文

BioLargo (BioLargo) Debt-to-EBITDA : -0.47 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is BioLargo Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioLargo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.41 Mil. BioLargo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.29 Mil. BioLargo's annualized EBITDA for the quarter that ended in Dec. 2023 was $-3.65 Mil. BioLargo's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.46.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioLargo's Debt-to-EBITDA or its related term are showing as below:

BLGO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83   Med: -0.39   Max: -0.02
Current: -0.4

During the past 13 years, the highest Debt-to-EBITDA Ratio of BioLargo was -0.02. The lowest was -0.83. And the median was -0.39.

BLGO's Debt-to-EBITDA is ranked worse than
100% of 1220 companies
in the Chemicals industry
Industry Median: 2.205 vs BLGO: -0.40

BioLargo Debt-to-EBITDA Historical Data

The historical data trend for BioLargo's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Debt-to-EBITDA Chart

BioLargo Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.41 -0.17 -0.29 -0.40

BioLargo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.86 -0.23 -0.24 -0.47

Competitive Comparison of BioLargo's Debt-to-EBITDA

For the Chemicals subindustry, BioLargo's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLargo's Debt-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioLargo's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioLargo's Debt-to-EBITDA falls into.



BioLargo Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioLargo's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.405 + 1.293) / -4.285
=-0.40

BioLargo's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.405 + 1.293) / -3.652
=-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioLargo  (OTCPK:BLGO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioLargo Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioLargo's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLargo (BioLargo) Business Description

Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
Linda Park director 14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray director PO BOX 234, FREDERICK CO 80530
Jack B. Strommen director 7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii director 1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan director 30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert director, 10 percent owner, officer: Chief Executive Officer 3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc 10 percent owner 16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan officer: Chief Financial Officer 8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano director, officer: Corporate Secretary 3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc. 10 percent owner 2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code 10 percent owner 16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison director
Eduardo Ruiz director, 10 percent owner